WebMD Health News

COVID-19 Vaccine Trial Shows Promise for Elderly

coronavirus vaccine

Sept. 29, 2020 -- An experimental vaccine against the virus that causes COVID-19 appears to generate more antibodies in people over the age of 70 than it does in even middle-aged adults.

If the antibody responses seen in the study translate into protection against the infection, the results could mean the elderly -- the population that has been hardest hit by COVID -- could receive strong protection from the shot. According to the CDC, eight out of 10 COVID-19 deaths in the U.S. have been in adults over age 65.

The vaccine, mRNA-1273, is made by the drug company Moderna, and it uses a new type of technology to coax the body to produce an immune response to the virus.

Basically, instructions for making the spike protein on the new coronavirus are injected into the body, where they are taken up by our cells. Cells then use those instructions to make the protein, which is released by the cells and recognized by the immune system. The immune system then makes weapons -- including antibodies -- against it. The hope is that when the real virus comes along, our bodies will have a jump-start and be ready to fight.

The study was small, with just 10 people included in each group, for a total of 40 people in the study. Results from the phase I trial of the vaccine show that adults over the age of 70 made roughly 3 times as many antibodies after their second dose, compared to adults ages 56 to 70.

“This is surprising because it has traditionally been observed that vaccine responses wane with age. Stated another way, antibody responses are usually lower with older age,” says Wilbur Chen, MD, who specializes in vaccine development in older adults at the University of Maryland. He was not involved in the study.

Traditional vaccines don’t usually work as well in the elderly, who are often the group most vulnerable to infections. Vaccine developers typically need to create special high-dose shots, or vaccines with added ingredients to stimulate the immune system -- called adjuvants -- in order to generate good protection.

“These findings could have profound significance if the protection afforded by vaccination among older adults is stronger than that of young adults because older adults are a very important target population for which we are targeting for protection with vaccination,” Chen says.

The purpose of the first phase was to assess safety and determine the most effective dose. Side effects seen in the first study included fatigue, chills, headache, muscle soreness, and pain at the site of the shot.

No placebo shots were given. Instead, recipients received two doses of either 25 micrograms or 100 micrograms given 4 weeks apart. The higher dose generated more antibodies in both groups. It also generated more side effects, including swelling and muscle soreness that lasted several days in some participants.

About 4 weeks after the 25-microgram shots, younger participants made an average antibody concentration of 323,945, while those ages 71 and up made an average concentration of 1,128,391 antibodies. After the 100-microgram shots, those ages 56-70 made an average concentration of 1,183,066 antibodies, compared to 3,638,522 in the older group.

The antibody responses measured in the study don’t necessarily mean that people are protected from infection. Researchers won’t know whether vaccination is protective until the end of the phase III trial, which is underway. But they are an encouraging sign.

“We were happy to see that the 100-microgram dose generated similar antibodies to those observed in 18- to 55-year-old recipients of the vaccine,” says Evan Anderson, MD, an associate professor of pediatric infectious disease at Emory University School of Medicine. The results from the younger adults were reported in an earlier study.

It’s not clear why this vaccine appears to generate such strong antibody responses, even among the elderly. “We don’t understand exactly why these immune responses in the older adults were still robust,” he says.

The study authors write that the antibody responses seen after the second dose of the vaccine are similar to those observed in patients who had recovered from COVID-19 and who had donated their blood for convalescent plasma. But they also note that right now, we don’t have a reliable biomarker that can tell us when someone is adequately protected against the virus.

The results were published today in TheNew England Journal of Medicine.

WebMD Health News Reviewed by Hansa D. Bhargava, MD on September 29, 2020


The New England Journal of Medicine, Sept. 29, 2020.

Wilbur Chen, MD, professor, University of Maryland School of Medicine; chief, Adult Clinical Studies section, Center for Vaccine Development and Global Health, Baltimore.

Evan Anderson, MD, associate professor of pediatric infectious disease, Emory University School of Medicine, Atlanta.

© 2020 WebMD, LLC. All rights reserved.